Production/Supply Archives - EMEA

This site provides INTERCEPT product information for International audiences .

Stanford Blood Center – the first blood center of its size to implement pathogen reduction for 100% of platelet components

Stanford Blood Center – the first blood center of its size to implement pathogen reduction for 100% of platelet components

by jaycornell | May 6, 2025

Stanford Blood Center California, United States

Experiences of standardized volume, pathogen-reduced, pooled plasma for faster availability of components for transfusion

Experiences of standardized volume, pathogen-reduced, pooled plasma for faster availability of components for transfusion

by jaycornell | May 6, 2025

Ms. Marja-Kaisa Auvinen, MD, PhD Uppsala University Hospital Uppsala, Sweden

Overview of the variability in platelet production processes and applied safety measures

Overview of the variability in platelet production processes and applied safety measures

by jaycornell | May 6, 2025

Dr. Mohammad R. Abedi, MD, PhD Örebro University Hospital Stockholm, Sweden

Case study: impact of pathogen inactivation on outdating rates and supply continuity

Case study: impact of pathogen inactivation on outdating rates and supply continuity

by jaycornell | May 6, 2025

Ms. Ragna Landrö, BSc The Blood Bank The National University Hospital of Iceland Reykjavík, Iceland

Case study: enabling double dose methodology on Reveos through pathogen inactivation

Case study: enabling double dose methodology on Reveos through pathogen inactivation

by jaycornell | May 6, 2025

Ms. Eleonore Tennby Cerus Europe B.V. Amersfoort, the Netherlands

« Older Entries